PepGen Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
May 14, 2024 16:02 ET
|
PepGen Inc.
– CONNECT1-EDO51 trial preliminary data from 5mg/kg dose cohort expected mid-2024 – – FREEDOM1-DM1 trial preliminary data from at least 5mg/kg dose cohort expected second half 2024 – – Net...
Edo Japan is Recognized for Multi-Year Awards in Franchise Excellence at the Canadian Franchise Association National Convention
April 18, 2024 08:00 ET
|
Edo Japan
Calgary, Alta., April 18, 2024 (GLOBE NEWSWIRE) -- Edo Japan was honoured with a ‘Multi-Year Streaks Award’ in the Franchisee Choice Awards at the 2024 Canadian Franchise Association (CFA) Awards of...
Decklar Resources Updates Crude Oil Injection Volumes From the Oza Oil Field Through the Trans Niger Pipeline and Sales to Local Refinery
March 27, 2024 08:30 ET
|
Decklar Resources Inc.
Decklar Resources Inc. and its co-venturer Millenium Oil & Gas Company Limited announce continued crude oil injection volumes from the Oza Oil Field through the Trans Niger Pipeline to the Bonny...
PepGen to Participate in Upcoming Investor Conferences
March 13, 2024 16:05 ET
|
PepGen Inc.
BOSTON, March 13, 2024 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming...
PepGen Receives U.S. FDA Orphan Drug and Rare Pediatric Disease Designations for PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy
March 13, 2024 07:00 ET
|
PepGen Inc.
BOSTON, March 13, 2024 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming...
DISQO’s Cross-Media Ad Measurement Now Amplified By Inscape’s Smart TV Viewing Data
March 11, 2024 07:00 ET
|
DISQO, Inc.
Brand experience platform DISQO is now connected to Inscape’s automatic content recognition (ACR) TV viewing data to strength cross-media ad measurement.
PepGen Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Developments
March 06, 2024 16:01 ET
|
PepGen Inc.
- Enrollment completed for PGN-EDO51 5 mg/kg cohort in CONNECT1-EDO51 Phase 2 clinical trial in DMD patients. The Company expects to announce preliminary data from the 5 mg/kg dose cohort in mid-2024...
PepGen Announces Clearance of CTA by UK Medicines & Healthcare Products Regulatory Agency to Begin CONNECT2-EDO51, a Phase 2 Clinical Trial designed to support potential accelerated approval of PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy
March 04, 2024 07:00 ET
|
PepGen Inc.
BOSTON, March 04, 2024 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming...
Edoc Acquisition Corp. Announces Postponement of Special Meeting of Shareholders on Proposed Business Combination
February 27, 2024 17:32 ET
|
Edoc Acquisition Corp.
Victor, NY, Feb. 27, 2024 (GLOBE NEWSWIRE) -- EDOC Acquisition Corp. (Nasdaq: ADOC) (“EDOC”) announced today that it has postponed its extraordinary general meeting of its shareholders (the...
Edoc Acquisition Corp. Announces Postponement of Special Meeting of Stockholders on Proposed Business Combination
February 23, 2024 17:45 ET
|
Edoc Acquisition Corp.
Victor, NY, Feb. 23, 2024 (GLOBE NEWSWIRE) -- EDOC Acquisition Corp. (Nasdaq: ADOC) (“EDOC”) announced today that it has postponed its extraordinary general meeting of its shareholders (the...